Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Keeps Outperform Rating at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a report issued on Tuesday, Benzinga reports. They currently have a $40.00 price target on the stock. Wedbush’s price objective points to a potential upside of 95.12% from the stock’s previous close.

Several other research firms also recently commented on DMRA. Jefferies Financial Group started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim increased their price objective on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Finally, TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $46.50.

Read Our Latest Research Report on DMRA

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $20.50 on Tuesday. Damora Therapeutics, Inc. Common Stock has a 1 year low of $3.64 and a 1 year high of $38.33. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -6.08 and a beta of 1.43. The business’s 50 day moving average price is $27.42 and its 200-day moving average price is $26.05.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. On average, sell-side analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Insider Activity

In related news, CEO Jennifer Jarrett bought 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. The trade was a 2.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.40% of the stock is owned by company insiders.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $303,000. Arizona State Retirement System acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $260,000. Seven Fleet Capital Management LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

Read More

Analyst Recommendations for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.